Kevin N. Heller, MD

Dr. Heller received his Bachelor’s degree in molecular biophysics and biochemistry from Yale University and his medical degree from George Washington University before training first in pediatrics and then pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center. Following fellowship, Dr. Heller joined the faculty of the Rockefeller University as Instructor and subsequently Chief Clinical Scholar of Clinical Investigation in the laboratory of Ralph Steinman. During this time, he served as principal investigator on clinical trials, including conducting and publishing his own NIH-funded research into T-cell mediated immune responses among patients with EBV-mediated lymphomas.

Dr. Heller began his industry experience at BMS where he led early development programs and was responsible for authoring and managing first-in-human clinical trials. Later as US medical lead for the treatment ipilimumab, he led the writing of the FDA approved label and the REMS-Side Effect Guidelines for ipilimumab. In this role he also represented BMS in the negotiation of payer policies. He also served as Global Lead for Oncology Search and Evaluation in the strategic transactions group at BMS where he was responsible for leading due diligence activities and prepared recommendations for possible acquisitions. At AstraZeneca, Dr. Heller was the medical lead for selumetinib and vandetanib programs in which he presented end of Phase 2 development plans to EMA (selumetinib program) and led the filing processes in China and Japan (including the authoring of the vandetanib Japan-PI). At Incyte, he served as head of antibody clinical development where he led the IND submissions of two novel immunotherapies and coordinated immunotherapy clinical development strategies for multiple antibody programs. Dr. Heller is currently the Chief Medical Officer at Tallac Therapeutics.